Combined use of androgen synthesis inhibitors and PARP inhibitors for the treatment of prostate cancer
Combining PARP inhibitors with androgen synthesis inhibitors addresses the limitations of current prostate cancer treatments by enhancing therapeutic efficacy and reducing toxicity, particularly in metastatic castration-resistant prostate cancer.
Patent Information
- Application Number
- TW114142931
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-03-21
- Filing Date
- 2025-11-04
- Publication Date
- 2026-08-01
AI Technical Summary
Current treatments for prostate cancer, particularly metastatic and castration-resistant forms, face challenges in efficacy and hematological toxicity, especially with PARP1 inhibitors, necessitating a more selective approach.
Combining PARP inhibitors, such as compounds represented by Formula 1, with androgen synthesis inhibitors like abiraterone, to develop a pharmaceutical composition for treating prostate cancer, with specific dosages and administration frequencies tailored for improved therapeutic outcomes.
The combination therapy significantly reduces PSA levels and disease progression, demonstrating high objective response rates and disease control in patients with metastatic castration-resistant prostate cancer, including those with BRCA mutations, while minimizing hematological toxicity.